ALLMedicine™ Detailed topics Center - Drugs
Learn More Information About Now FDA-Approved KOSELUGO On The Official Site. Resources Available. Important Safety Info. Indication Info. Download Prescribing Info. Access 360 Program. Insurance coverage: Financial Support Info, Access 360 Program.
Apr 28th, 2020 - The Food and Drug Administration approved niraparib (ZEJULA, GlaxoSmithKline) for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy.
May 5th, 2020 - On May 6, 2020, the Food and Drug Administration granted accelerated approval to capmatinib (TABRECTA, Novartis) for adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.
View Safety & Prescribing Information On The Official Patient Site. Learn How Retevmo™ Works And How It May Help Eligible Patients. Savings & Support. Dosing and Administration. About RETEVMO™. Types: Patient Resources, Treatment Information, Safety Information.
(daratumumab and hyaluronidase human-fihj) Learn More at the Official Physician Site. Prescription Assistance. Patient Support Program. Dosing Admin & Safety. Janssen CarePath. Official Physician Site. Learn About Multiple MOAs. Patient Dosing Schedule.
HCPs, Visit The Official Site For Information About TABRECTA™ As A Treatment Option. See If TABRECTA™ Could Be Right For Your Patients. Full Safety Profile. Patient Co-Pay Program. Mechanism Of Action. Newly FDA Approved. Official HCP Website. Clinical Trial Data.
Visit our website to find information on efficacy, safety, and dosing. HCP Resources. Treatment Sequencing. Patient Stories. Prescribing Information. Dose Modification. Zejula ovarian cancer niraparib Zejula
ACT® Advanced Care™ Plaque Guard™ | ACT® Anticavity Fluoride Rinse
CERDELGA is a glucosylceramide synthase inhibitor indicated for the long-term treatment of adult patients with Gaucher disease type 1 who are CYP2D6 extensive metabolizers (EMs), intermediate metabolizers (IMs), or poor metabolizers (PMs) as detected by an FDA-cleared test.
Adempas (riociguat). Visit Adempas-US.com to see full safety and prescribing information, including Boxed Warning. Learn about Adempas and the Aim Patient Support Program.
Acnizil™ is a new first-line therapy product for mild to severe acne. It is made from a proprietary silver solution
An in vitro polymerase chain reaction (PCR) assay for the qualitative detection of single nucleotide variants (SNVs)
Find valuable ACTEMRA® (tocilizumab) information, including an ACTEMRA® dosing calculator, RA patient brochure, ACTEMRA® prescription guide and the ISI. IMPORTANT SAFETY INFORMATION-RA: ACTEMRA is a prescription medicine called an interleukin-6 (IL-6) receptor antagonist.
Explore AcrySof IQ intraocular lenses for your cataract surgery and the AcrySof® Advantage at myalcon.com.
Learn about Adlyxin™ (lixisenatide) injection, a GLP-1 receptor agonist to help improve glycemic control in adults with type 2 diabetes indicated as an adjunct to diet and exercise.
ABILIFY MAINTENA for the treatment of schizophrenia and the maintenance treatment of bipolar I disorder in adult patients. See full Safety and Prescribing Information, including BOXED WARNING.
ADCIRCA is a trademark of Eli Lilly and Company. http://pi.lilly.com/us/adcirca-ppi.pdf. Please see Important Safety Information and Full Prescribing Information.
The first and only FDA-approved treatment indicated to slow kidney function decline and kidney cyst growth in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD).
ACTICLATE® (doxycycline hyclate USP) Tablets are indicated for adjunctive therapy in severe acne. Click here for Full Prescribing Information for ACTICLATE® Tablets. Important Safety Information Regarding ACTICLATE® (doxycycline hyclate USP) Tablets, 150 mg and 75 mg.